Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Aug 12, 2013

The 20 Top Paid Women Executives in Biopharma

Who are the highest-paid females in the industry this year?

The 20 Top Paid Women Executives in Biopharma

See how well these 20 sisters are doin’ it for themselves. [© stefa_neve - Fotolia.com]

  • #10. Jacqualyn A. Fouse, Ph.D.

    Company: Celgene

    Title: EVP and CFO

    2012 Compensation: $3,450,103

    2011 Compensation: $2,535,033

    % Change: 36.1%

  • #9. Robin L. Washington

    Company: Gilead Sciences

    Title: SVP and CFO

    2012 Compensation: $4,175,593

    2011 Compensation: $4,032,193

    % Change: 3.6%

  • #8. Sandra Peterson

    Company: Johnson & Johnson

    Title: Group Worldwide Chair

    2012 Compensation: $4,698,8506

    2011 Compensation: N/A6

    % Change: N/A6

  • #7. Silvia Ayyoubi

    Company: Roche

    Title: Head, Group Human Resources

    2012 Compensation: $5,346,932 (CHF 4,970,897)1

    2011 Compensation: $4,342,348 (CHF 4,037,074)1,7

    % Change: 23.1%

  • #6. Amy W. Schulman

    Company: Pfizer

    Title: EVP and General Counsel; Business Unit Lead, Consumer Healthcare

    2012 Compensation: $5,573,218

    2011 Compensation: $5,764,662

    % Change: -3.3%

  • #5. Sandra Leung

    Company: Bristol-Myers Squibb

    Title: General Counsel & Corporate Secretary

    2012 Compensation: $5,892,772

    2011 Compensation: $5,491,673

    % Change: 7.3%

  • #4. Martine Rothblatt

    Company: United Therapeutics

    Title: CEO

    2012 Compensation: $7,958,328

    2011 Compensation: $3,161,350

    % Change: 151.7%

  • #3. Heather Bresch

    Company: Mylan

    Title: CEO

    2012 Compensation: $8,000,628

    2011 Compensation: $9,208,0348

    % Change: -13.1%

  • #2. Beatrice Cazala

    Company: Bristol-Myers Squibb

    Title: EVP, Commercial Operations

    2012 Compensation: $8,031,025

    2011 Compensation: $5,941,1679

    % Change: 35.2%

  • #1. Laura J. Schumacher

    Company: AbbVie

    Title: EVP, Business Development, External Affairs and General Counsel

    2012 Compensation: $10,192,74810

    2011 Compensation: $5,567,49310

    % Change: 83.1%



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »